Literature DB >> 16426841

Clinico-histologic parameters of osteosarcoma patients with late relapse.

E I Hauben1, S Bielack, R Grimer, G Jundt, P Reichardt, M Sydes, A H M Taminiau, P C W Hogendoorn.   

Abstract

Primary high-grade intramedullary osteosarcoma of the extremities is a clinically aggressive bone tumour. There is an ongoing effort to further improve efficacy of neo-adjuvant chemotherapy and reduce chemotoxicity by trying to identify osteosarcoma patients who are at risk of treatment failure as well as to identify those who can do with less chemotherapy. In only 5% of patients, first distant metastasis or local relapse occurs 5 years or more after initial treatment for osteosarcoma. Patients and physicians can therefore easily erroneously consider a patient with osteosarcoma cured if he or she is disease-free for more than 5 years following diagnosis and treatment. To investigate if these rare late relapsing patients are characterised by specific clinico-pathological features, we examined clinical and histological variables of late relapse (first local recurrence or metastasis 5 years or more after initial diagnosis) out of a total of 2,243 patients, with a special interest in the histological osteosarcoma subtype. In total, 33 patients had a documented relapse 5 years or more after diagnosis. Half of the patients had good response (>or=90% necrosis) to pre-operative chemotherapy and the other half a poor response (<90% necrosis) and late relapses seemed to be more frequently proportionately in those who had a good initial response to chemotherapy. The occurrence of late relapse did not appear to be associated with age or gender. Although not statistically significant, there was a trend for patients with a chondroblastic subtype of osteosarcoma, or a location in the tibia or fibula, to have a higher risk for late relapse.

Entities:  

Mesh:

Year:  2006        PMID: 16426841     DOI: 10.1016/j.ejca.2005.09.032

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  16 in total

Review 1.  Pathology of primary malignant bone and cartilage tumours.

Authors:  L B Rozeman; A M Cleton-Jansen; P C W Hogendoorn
Journal:  Int Orthop       Date:  2006-08-30       Impact factor: 3.075

2.  Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma.

Authors:  Bernd Kubista; Florian Klinglmueller; Martin Bilban; Martin Pfeiffer; Richard Lass; Alexander Giurea; Phillipp T Funovics; Cyril Toma; Martin Dominkus; Rainer Kotz; Theresia Thalhammer; Klemens Trieb; Teresa Zettl; Christian F Singer
Journal:  Int Orthop       Date:  2010-03-26       Impact factor: 3.075

Review 3.  The biology of small leucine-rich proteoglycans in bone pathophysiology.

Authors:  Dragana Nikitovic; John Aggelidakis; Marian F Young; Renato V Iozzo; Nikos K Karamanos; George N Tzanakakis
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

4.  Short-term and long-term prognostic value of histological response and intensified chemotherapy in osteosarcoma: a retrospective reanalysis of the BO06 trial.

Authors:  Eni Musta; Nan van Geloven; Jakob Anninga; Hans Gelderblom; Marta Fiocco
Journal:  BMJ Open       Date:  2022-05-10       Impact factor: 3.006

Review 5.  Management of osteosarcoma.

Authors:  Jeremy Whelan; Beatrice Seddon; Martha Perisoglou
Journal:  Curr Treat Options Oncol       Date:  2006-11

Review 6.  Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.

Authors:  J PosthumaDeBoer; M A Witlox; G J L Kaspers; B J van Royen
Journal:  Clin Exp Metastasis       Date:  2011-04-02       Impact factor: 5.150

7.  mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts.

Authors:  Marieke L Kuijjer; Heidi M Namløs; Esther I Hauben; Isidro Machado; Stine H Kresse; Massimo Serra; Antonio Llombart-Bosch; Pancras C W Hogendoorn; Leonardo A Meza-Zepeda; Ola Myklebost; Anne-Marie Cleton-Jansen
Journal:  BMC Med Genomics       Date:  2011-09-20       Impact factor: 3.063

8.  Late recurrence in pediatric cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Karen Wasilewski-Masker; Qi Liu; Yutaka Yasui; Wendy Leisenring; Lillian R Meacham; Sue Hammond; Anna T Meadows; Leslie L Robison; Ann C Mertens
Journal:  J Natl Cancer Inst       Date:  2009-12-16       Impact factor: 11.816

9.  Late post-operative recurrent osteosarcoma: Three case reports with a review of the literature.

Authors:  Xiuchun Yu; Sujia Wu; Xuquan Wang; Ming Xu; Songfeng Xu; Ye Yuan
Journal:  Oncol Lett       Date:  2013-04-29       Impact factor: 2.967

Review 10.  Very late relapse of high-grade osteosarcoma: A case report and review of the literature.

Authors:  Yoichi Kaneuchi; Michiyuki Hakozaki; Hitoshi Yamada; Osamu Hasegawa; Shoki Yamada; Yuka Oka; Kazuo Watanabe; Shinichi Konno
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.